Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.

TransMedics (Andover, MA) a clinical-stage medical device company focused on a technology platform to maintain donor organs in near-physiologic and functioning condition during transport for organ transplantation, closed a $36M Series E financing. Participants include Foundation Capital, Kleiner Perkins Caufield & Byers, Flagship Ventures, 3i Group, Tudor Investment, VantagePoint Venture Partners, Sherbrooke Partners, Alta Partners, [...]